SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff following reports of a major Binance security breach is the main pressure on Strategy, whose shares traders view as closely tied to BTC. The community is split between buying the dip and warning that crypto-security concerns, alongside Strategys revenue miss and CFO transition, could weigh further on the stock.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a fresh 52-week high ahead of the upcoming Q3 report has traders focused on BRIUMVIs sales ramp and managements outlook; some point to earnings expectations, while others speculate about an unconfirmed buyout and short covering.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could fall after the first quarter of 2027 has fueled concerns about CorMedixs pricing and revenue, alongside a sharp selloff. Traders disagree on how much weight to give DaVitas preliminary outlook, with some pointing to CMSs published reimbursement estimate while others see ongoing pressure ahead.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach is driving concern about exchange safety, possible withdrawals and selling pressure across crypto. Traders are divided between expecting further downside from shaken confidence and viewing Bitcoins relative resilience as a buying opportunity, arguing the breach affects the exchange rather than Bitcoins network.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and concern over oil-supply disruptions tied to Middle East tensionsespecially risks to shipping and refiningdominate the discussion around XLE. Traders point to the rally and energys relative strength as bullish, while others warn that diplomatic progress, profit-taking, or an overextended move could weigh on the fund.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is focused on upcoming Q3 results and the Casgevy sales update, with traders debating whether rising patient starts and treatment-center expansion will translate into stronger collaboration revenue. The upcoming CTX310 clinical presentation is another key catalyst; sentiment is mixed between anticipation of data-driven progress and concern about the stocks decline and CFO transition.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and outlook are fueling discussion of its potential to benefit from rising natural-gas demand for AI data centers and other power customers. Many traders are bullish on that growth and the distribution, while others are frustrated that the unit price has not responded more strongly.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector selloff, with traders citing broad technical breakdowns and weakness in semiconductors and other tech groups. The conversation is mostly bearish, though some see the pullback as a potential buying opportunity or expect a bounce; confirmation of support remains a key debate.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp AMP rally and volume spike have traders speculating about renewed interest in the Flexa/Anvil payment-infrastructure thesis and AMPs collateral role. Others say there is no confirmed new catalyst and warn the move may be another short-lived pump.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases post-earnings selloff is drawing attention as traders weigh weak underlying crypto-trading activity and a revenue shortfall against headline profitability, much of which they attribute to gains on crypto holdings. A Bitcoin slide and Binance hack concerns are adding pressure, though some traders view the decline as an overreaction or buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Equity

The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application

Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market. 


Biotech Whiplash: Big Pharma Setbacks Just Created a New Wave of Rebound Plays

The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: a great company can get crushed by bad news somewhere else in the pipeline. A Novartis (NYSE:NVS) setback rippled through the biotech space, yesterday, dragging down companies whose own announcements were positive.

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million.
bioAffinity Technologies (NASDAQ:BIAF) stockread more...

Five Market Stories Heating Up Right Now

The latest market developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity; Sunation Energy (NASDAQ:SUNE) is positioned at the center of Suniva’s $835 million financing and planned expansion to 5.5 GW of U.S. solar-cell capacity; and The OLB Group (NASDAQ:OLB) is attempting to build a rebound momentum after recently hitting a new 52-week low and, yes, I know that’s a sixth company.

Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.read more...

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.read more...

Five High-Voltage Stories in Focus

The market is once again rewarding investors who know where to look for catalysts, bioAffinity Technologies (NASDAQ:BIAF), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), Eos Energy Enterprises (NASDAQ:EOSE) with Google (NASDAQ:GOOG), and Scorpio Gold (NASDAQ:SGLD) each have a distinctly different catalyst driving their narratives.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Ryzumvi contains phentolamine ophthalmic solution 0.75%, which reduces pupil size to improve near vision without affecting longer-distance vision.</li><li>The approval was supported by two Phase 3 trials.</li><li>Opus is studying Ryzumvi for vision problems in dim lighting after laser eye surgery.</li></ul>Opus Genetics (IRD) was in the spotlight on Friday, after the U.S. Food and Drug Administration approved its eye drop for treating presbyopia, an age-related condition that makes it difficult to focus on nearby objects.The approval expands the use of an already commercialized therapy and triggers a milestone payment from commercial partner Viatris (VTRS).At the time of writing, <a class="mention" data-mention="$IRD" data-symbol-id="IRD" href="https://stocktwits.com/symbol/IRD" target="_blank">IRD shares</a> were trading 3.4% lower, while <a href="https://stocktwits.com/symbol/VTRS">VTRS stock</a> gained about 1%.<h2 class="st-heading-2">Approval Based On Two Phase 3 Trials</h2>Opus’ Ryzumvi contains phentolamine ophthalmic solution 0.75%, which reduces pupil size to improve near vision without affecting longer-distance vision. The approval was supported by two Phase 3 trials, VEGA-2 and VEGA-3, which met their primary and key secondary goals without serious treatment-related side effects.Notably, 27.2% of patients receiving the eye drop saw an improvement of at least 15 letters (three lines) on an eye chart, compared with 11.5% receiving a placebo.The drug previously received <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-25-011410/ef20039022_10k.htm">FDA approval</a> in September 2023 to reverse pupil dilation caused by medications used during eye examinations. Viatris launched it commercially in April 2024.The companies’ licensing <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm">agreement</a> dates back to November 2022, when Ocuphire Pharma, which acquired Opus in October 2024, granted Viatris the rights to commercialize the treatment.The agreement included $35 million upfront, up to $130 million in milestone payments, and royalties.<h2 class="st-heading-2">IRD Finances To Support Operations Into 2029</h2>Opus is developing gene therapies for inherited retinal diseases, including OPGx-BEST1 for Best disease and OPGx-LCA5 for severe inherited vision loss. The company is also studying Ryzumvi for vision problems in dim lighting following laser eye surgery.Opus reported $88.8 million in cash and cash equivalents as of June 30, and has a financing option of up to $120 million under an agreement with Oberland Capital. The company expects its cash position to support operations into 2029.<h2 class="st-heading-2">IRD, VTRS See Strong Gains In 2026</h2>Retail sentiment surrounding both IRD on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. Meanwhile, sentiment for VTRS remained ‘neutral’.IRD shares have seen strong buying interest so far this year, surging 84%. Meanwhile, VTRS stock has gained about 48%.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/mi-medx-sanara-merger-faces-fresh-regulatory-obstacle-smti-stock-falls-below-this-key-support-level-for-the-first-time-in-4-months/cZxKJ0GRBsM">MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Viatris Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.67
Prev Close	$3.65
Open	$3.58
Dividend Yield	0.00%
50-Day Moving Average	$4.47
Beta	1.07
Avg. Volume	5.18M
PE Ratio	-2.67

52-Week High	$7.07
52-Week Low	$1.70
Market Capitalization	$305.33M
EPS (Annual)	-$0.797
Price to Book	-23.36
Revenue Per Employee	$507,000.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IRD Fundamentals